Physician profile
Stanley L Combs
NPI 1932200938
$12,000.25
in general payments reported to CMS, 2019-2025
67 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $1,870 · 2021: $2,290 · 2022: $1,841 · 2023: $1,586 · 2024: $1,555 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,373.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,307.39 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,074.39 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,072.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,059.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $919.90 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Pfizer INC. | $731.41 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $615.16 | 2019-2023 | |
| Amgen INC. | $481.92 | 2019-2025 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $425.94 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $420.53 | 2019-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $272.01 | 2019-2025 | |
| Astellas Pharma US INC | $251.37 | 2019-2025 | Veozah |
| Eisai INC. | $241.05 | 2020-2025 | |
| Abbott Laboratories | $221.46 | 2019-2025 | Freestyle Libre 3, Proclaim, Assurity |
| Sumitomo Pharma America, INC. | $194.08 | 2024-2025 | Gemtesa |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.